BSEBoard Meeting3d ago · 27 Jul 2026, 08:45 pm

Anlon Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2026 ,inter alia, to consider and approve 1. To consider and approve ....

Anlon Healthcare Ltd · 544497

✦ AI SummaryResults

Anlon Healthcare Ltd has scheduled a board meeting on July 30, 2026, to consider and approve unaudited financial results for the quarter ended June 30, 2026, and to authorize a share swap arrangement with shareholders of Apiqo Organics Private Limited and Bizotic LifeScience Private Limited.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk5/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Anlon Healthcare Ltd - 544497 - Board Meeting Intimation for Declaration Of Financial Results For The Quarter Ended June 30, 2026

Attachments (1)

📄

4a663de3-4f66-4eb8-8088-03cd04f2bebd.pdf

pdf

Download →
View document text
July 27, 2026 To, To, Listing Department, The National Stock Exchange of India BSE Limited Ltd. Phiroze Jeejeebhoy Towers, The Listing Department Dalal Street, Exchange Plaza, Mumbai – 400 001 Bandra – Kurla Complex, Ref: BSE Scrip Code: 544497 Mumbai – 400051, NSE Scrip Code: AHCL Sub: Prior Intimation for Board Meeting of ANLON HEALTHCARE LIMITED Respected Sir/Madam, With reference to above captioned Subject and in Compliance with Regulation 29 and 33 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015, this is to inform you that the Meeting of the Board of Directors of the Anlon Healthcare Limited (“Company”) is scheduled to be held on Thursday, July 30, 2026, at the registered office of the company, inter alia, to consider and approve the following businesses: 1. To consider and approve the Unaudited Standalone and Unaudited Consolidated Financial Results of the Company for the Quarter ended June 30, 2026 along with the Limited Review of Auditors thereon. 2. To authorize Mr. Punitkumar Rasadia, Chairman & Managing Director and/or Mr. Meet Vachhani, Whole Time Director of the Company, for entering into a share swap arrangement with the shareholders of Apiqo Organics Private Limited (“AOPL”) and Bizotic LifeScience Private Limited (“BLPL”) to acquire [32.52%] shareholding in AOPL and [43.33%] shareholding in BLPL, to make both these entities as wholly owned subsidiaries, in lieu of issuance and allotment of the fresh equity shares of the Company on a preferential basis for consideration other than cash, to such selling shareholders. 3. Any other business(s) with permission of the Chair, if any. You are requested to take the above information on your record Thanking You. Yours Faithfully, FOR, ANLON HEALTHCARE LIMITED PUNITKUMAR RASADIA MANAGING DIRECTOR DIN: 06696258 ANLON HEALTHCARE LIMITED CIN No.: U24230GJ2013PLC077543 REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot- 360005, Gujarat (INDIA) PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in